CN105218617A - A kind of new triterpenoid and preparation method thereof and medicinal use - Google Patents
A kind of new triterpenoid and preparation method thereof and medicinal use Download PDFInfo
- Publication number
- CN105218617A CN105218617A CN201510640790.4A CN201510640790A CN105218617A CN 105218617 A CN105218617 A CN 105218617A CN 201510640790 A CN201510640790 A CN 201510640790A CN 105218617 A CN105218617 A CN 105218617A
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- extract
- preparation
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a kind of new triterpenoid and preparation method thereof and medicinal use.This compound is reported first, is a kind of triterpene compound of novel structure, can obtain by extracting and developing purifying from the dry leave of Cornus controversa.In vitro tests proves that this compound effectively can suppress the growing multiplication of HepG2 cell, and the survival rate of intervention group cell comparatively control group significantly reduces, and reduces degree and compound (I) concentration presents certain dosage effect trend.Compound (I) has potential using value in Hepatoma therapy, can be used for being developed to the medicine of Hepatoma therapy.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry leave of Cornus controversa, be separated obtain a kind of and there is triterpene compound of Hepatoma therapy effect and preparation method thereof.
Background technology
Cornus controversa Alstoniascholaris (L.) R.Br. is Apocynaceae Alstonia arbor.Its nature and flavor are sweet, light, flat, have the effect such as clearing heat and detoxicating, swelling and pain relieving, antiasthmatic-antitussive, preventing malaria, sweating, stomach invigorating.Lamp stand tree root, stem, skin, Ye Junke are used as medicine, with skin and Ye Weizhu.This plant is mainly distributed in the south Guangxi of China, western part and south of Yunnan, also has distribution in Nepal, India, Sri Lanka, Burma, Thailand, Vietnam, Cambodia, Malaysia, Indonesia, Philippines and Australian torrid areas.Cornus controversa has long medication history among the people, and China's lamp stand bark treatment among the people headache, cold, eruptive disease, pneumonia, Whooping cough, chronic bronchitis, external application can control trauma hemostasis, synthetism, detumescence, sore furuncle and preparation agrochemical.
Chinese scholars has carried out a series of research to the chemical composition of Cornus controversa, and the chemical composition had been found that mainly comprises alkaloids, flavonoid and triterpenes, secondly also has the compositions such as volatile oil, steroid, VITAMIN.At present, the research of the alkaloid of Cornus controversa, flavones and triterpenes components is comparatively deep, wherein more with the research of lamp stand leaf, is therefrom separated and obtains more than 50 alkaloid component, be mainly monoterpenoid indole alkaloid.
In recent years, along with the progressively expansion to its aspect such as chemical composition and pharmacologically active research, find that its activeconstituents enriches, in antitumor, anti-inflammatory, antibacterial, anti-diabetic and Adjust-blood lipid etc., demonstrate potential pharmaceutical use.Research shows, the cell of triterpenes components Lupeol to different tissue sources contained in Cornus controversa all has proliferation inhibition activity, as melanoma 451LU cell, WM35 cell and B162F2 cell, human pancreas cancer cell strain AsPC-1, people's epidermal carcinoma A431 cell, liver cancer SMMC7721 cell, prostate cancer cell LNCaP, CWR22R γ 1 and PC-3.Lupeol optionally suppresses the propagation of nude mouse 451LU and CWR22R γ 1 cell, plays a role by regulating the expression in tumor xenograft of cell proliferation markers, apoptosis markers and cell cycle regulatory molecules.Cornus controversa except there is above pharmacological action, also have bring down a fever, contracting palace, step-down, the effect such as anti-malarial.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry leave of Cornus controversa, be separated obtain a kind of there is triterpene compound of Hepatoma therapy effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry leave of (a) Cornus controversa is pulverized, extract with 75 ~ 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 75% ethanol elution, 12 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,30:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, in step (a), extract with 80% alcohol heat reflux, united extraction liquid.
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
A kind of pharmaceutical composition, this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
Described compound (I) application in the medicine preparing Hepatoma therapy.
The application of described pharmaceutical composition in the medicine preparing Hepatoma therapy.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value;
Fig. 3 compound (I) is on the impact (n=3) of HepG2 and L02 cell proliferation.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry leave (8kg) of Cornus controversa is pulverized by (a), (25L × 3 time) are extracted with 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (355g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, use 75% ethanol elution, 12 column volumes again, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract (136g); C in () step (b), 75% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 80:1 (8 column volumes), the methylene chloride-methanol gradient elution of 50:1 (8 column volumes), 30:1 (6 column volumes), 10:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (31g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 15:1 (8 column volumes), the methylene chloride-methanol gradient elution of 10:1 (10 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (11g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (35mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z553.3508, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
32h
50o
6, degree of unsaturation is 8.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 500MHz): H-1 (1.83, m), H-1 (1.47, m), H-2 (1.59, m), H-2 (1.48, m), H-3 (4.44, dd, J=11.6, 4.2), H-5 (1.46, m), H-6 (1.88, m), H-6 (1.69, t, J=14.6), H-7 (2.93, d, J=6.4), H-11 (1.81, m), H-11 (1.93, m), H-12 (1.49, m), H-12 (1.90, m), H-15 (1.45, m), H-15 (1.16, ddd, J=12.5, 12.5, 5.3), H-16 (1.27, m), H-16 (2.06, m), H-17 (1.59, m), H-18 (0.97, s), H-19 (0.96, s), H-20 (1.33, m), H-21 (0.87, d, J=6.6), H-22 (0.99, m), H-22 (1.34, m), H-23 (1.76, m), H-23 (1.93, m), H-24 (4.97, tt, J=7.1, 1.4), H-26 (1.51, s), H-27 (1.59, s), H-28 (0.89, s), H-29 (0.90, s), 3-OAc (1.99, s), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 125Hz): 29.9 (CH
2, 1-C), 22.5 (CH
2, 2-C), 79.3 (CH, 3-C), 37.1 (C, 4-C), 41.8 (CH, 5-C), 20.2 (CH
2, 6-C), 53.1 (CH, 7-C), 64.0 (C, 8-C), 85.3 (C, 9-C), 37.1 (C, 10-C), 22.2 (CH
2, 11-C), 33.7 (CH
2, 12-C), 46.4 (C, 13-C), 59.1 (C, 14-C), 19.9 (CH
2, 15-C), 27.2 (CH
2, 16-C), 51.8 (CH, 17-C), 13.5 (CH
3, 18-C), 16.1 (CH
3, 19-C), 34.2 (CH, 20-C), 17.7 (CH
3, 21-C), 35.5 (CH
2, 22-C), 24.4 (CH
2, 23-C), 124.3 (CH, 24-C), 130.6 (C, 25-C), 17.1 (CH
3, 26-C), 25.3 (CH
3, 27-C), 27.6 (CH
3, 28-C), 16.3 (CH
3, 29-C), 176.8 (C, 30-C), 170.1 (C, 3-OAc), 21.1 (CH
3, 3-OAc), carbon atom mark is see Fig. 1.IR spectrum shows this compound and contains gamma lactone (1766cm
-1) and carbonyl (1727cm
-1) group.
1the display of HNMR spectrum is containing seven methyl signals δ H0.97 (H
3-18), 0.96 (H
3-19), 1.51 (H
3-26), 1.59 (H
3-27), 0.89 (H
3-28), 0.90 (H
3-29) and 1.99 (3-OAc), and a bimodal signal δ H0.87 (H
3-21, d, J=6.6Hz), illustrate that this compound is triterpene compound.
13cNMR and DEPT composes display 32 carbon signals, comprise eight methyl, six methynes (two containing oxygen methyne and an alkene carbon), nine methylene radical and nine quaternary carbons (two lactone carbonyl carbon, two containing oxygen carbon and an alkene carbon).In addition, side chain has 24 (25)-double bonds (δ C130.6,124.3 and δ H4.97, tt, J=7.1,1.4Hz) signal.In HMBC spectrum, H
3-26 and H
3-27 with C-24 and C-25; H
3-21 and C-17, C-20 and C-22; And H-24 and C-22, C-23, H
3-26 and H
3the above-mentioned inference of the relevance verification of-27.In addition, an ester carbonyl group signal [δ C176.8 (C-30)] and two carbon signals [δ C85.3 (C-9) and 59.1 (C-14)] illustrate that this compound exists a gamma lactone structure.In HMBC spectrum, H
3-18 and C-14; H
2-15 and C-30; H
2-11 and C-9; H-11 α and C-8 and H
3-19 with the relevance verification of C-9 the annexation of 30,9-these functional groups.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
HepG2 human hepatoma cell strain is purchased from Chinese Academy of Sciences's biological chemistry and Institute of Cell Biology.L02 normal liver cell strain presented by Zhong Shan hospital of Fudan University liver cancer research.Compound (I) is made by oneself, and HPLC normalization method purity is greater than 98%.RPMI-1640 substratum, pancreatin are purchased from Gibco company.Standard calf serum is purchased from Biowest company.3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromine salt (MTT), dimethyl sulfoxide (DMSO) (DMSO), trypan blue (TrypanBLue), dichlorofluorescein diacetate (DCFH-DA) is all purchased from Shanghai Chemical Reagent Co., Ltd., Sinopharm Group.Other common agents are analytical pure.
Microbalance (Switzerland plum Teller-Tuo benefit, METTLRERAE2000).Common desktop whizzer (Anting Scientific Instrument Factory, Shanghai).Digital display electric heating constant-temperature water-bath tank (Shanghai leap medical machinery factory, HH.W21.600S).Carbon dioxide cell incubator (FormaScientific company of the U.S.).High speed freezing centrifuge (Thermo company of the U.S., IECMICROMAXRF).Ultramicron ultraviolet spectrophotometer (ThermoHsher company of the U.S., NanoDrop-1000).Ultraviolet imagery system (Shanhai Furi Science and Technology Co., Ltd., FR-200A).Enzyme-linked immunosorbent assay instrument, spectrophotofluorometer (HitachiF2500).
Two, test method
1, cell cultures
Cell routine is inoculated in the RPMI-1640 substratum containing 10% (volume fraction) calf serum, is placed in 37 DEG C, 5%CO
2cultivate in the incubator of concentration.
2, compound (I) intervenes the configuration of nutrient solution
45.44mg compound (I) be dissolved in the obtained storing solution of 10mL dimethyl sulfoxide (DMSO) (DMSO) and dilute 2 times, 4 times respectively, obtaining compound (I) the application liquid of 2mmol/L, 4mmol/L and 8mmol/L respectively.Before carrying out cell intervention, 50 μ L application liquid are fully mixed with 4950 μ L cellar culture liquid (calf serum containing 10% volume fraction), obtains compound (I) and intervene nutrient solution (20 μm of ol/L, 40 μm of ol/L, 80 μm of ol/L).
3, mtt assay detects cell survival rate
The vegetative period cell of taking the logarithm is inoculated in 96 well culture plates, every hole 200 μ L (5 × 10
3cell).Cultivate 12h after cell attachment, discard original fluid, compound (I) nutrient solution adding 200 μ L different concns (mixes with cellar culture liquid with 1% volume fraction after DMSO dissolved compound (I), compound (I) final concentration is made to be 20 μm of ol/L, 40 μm of ol/L, 80 μm of ol/L), often organize 6 parallel holes.Establish 6 solvent (DMSO) control wells simultaneously.Cultivate 24h, 48h, 72h, within every 24 hours, change compound (I) and intervene nutrient solution.Intervene after terminating, suck nutrient solution, add 20 μ LMTT solution to each hole, 37 DEG C hatch 4h after suck each hole supernatant liquor, add 150 μ LDMSO, put low speed concussion 10min on shaking table, after abundant dissolving to be crystallized, with DMSO zeroing, measure each hole absorbancy with enzyme-linked immunosorbent assay instrument at 490nm place, calculate cell survival rate (survivalrate, SR).SR=experimental group A
490/ control group A
490× 100%
4, trypan blue Ran Se Measuring determines survivaling cell number
By equal amts (2 × 10
6) cell be inoculated in Tissue Culture Flask, cultivate for some time after cell attachment, discard nutrient solution, after washing twice, cell with PBS, the compound (I) adding 5mL intervenes nutrient solution (20 μm of ol/L, 40 μm of ol/L, 80 μm of ol/L).Often organize three bottles of cells, set up three bottles of solvent (DMSO) contrasts simultaneously.After cultivating 48h, use 0.25% trypsin digestion cell, collecting cell suspension, determination of trypan blue staining cell count.
5, DCFH-DA method measures ROS activity in cell
By equal amts (2 × 10
6) cell be inoculated in Tissue Culture Flask, cultivate for some time after cell attachment, suck original fluid, add 5mL compound (I) and intervene nutrient solution, after continuing to cultivate 48h, discard nutrient solution, trypsin digestion cell, collecting cell suspension is in 1.5mLEP pipe, the centrifugal 5min of 1500rpm, abandons supernatant, in precipitation, add 1mLDCFH-DA, piping and druming mixing, hatch 30min for 37 DEG C, add PBS termination reaction, centrifugal collecting precipitation is also dissolved in 1mLPBS, blow and beat uniformly cell suspension, burn light spectrophotometric determination fluorescent value with Hitachi-F2500.Excitation wavelength 488nm, emission wavelength 525nm.
Three, result and conclusion
1, Growth of Cells survival rate
HepG2 cell is after compound (I) intervention cultivates 24h, 48h, 72h, the cell survival rate of basic, normal, high dosage group is all remarkable in solvent control group (P<0.05), and the degree that declines of cell survival rate and compound (I) are intervened between concentration and be there is doses effect trend (table 1
ap<0.05VS control group;
bp<0.05VS low dose group;
cdosage group in P<0.05VS).Under same compound (I) intervenes concentration, cell survival rate presents downward trend along with the increase of intervention time.And under equal conditions, L02 Human normal hepatocyte is after compound (I) is intervened, cell survival rate is without noticeable change (table 2).Trypan Blue cell counts consistent with MTT (Fig. 3,
ap<0.05VS control group;
bp<0.05VS low dose group;
cdosage group in P<0.05VS).
2, in cell, ROS is active
HepG2 human liver cancer cell is after different concns compound (I) is intervened, and compared with control group, intracellular ROS level significantly declines (P<0.05).The results are shown in Table 3 (
ap<0.05VS control group;
bp<0.05VS low dose group).
Conclusion, the compound (I) of different concns is adopted to carry out intervention process to human liver cancer cell HepG2, show through MTT colorimetric and Trypan Blue cell counting, compound (I) effectively can suppress the growing multiplication of HepG2 cell, the survival rate of intervention group cell comparatively control group significantly reduces, and reduction degree and compound (I) concentration present certain dosage effect trend, simultaneously under same compound (I) concentration, cell survival rate presents the trend continuing to reduce along with the increase of intervention time.Meanwhile, compound (I) intervention of same dose does not produce restraining effect to L02 normal liver cell.
Table 1 compound (I) is on the impact (x ± s, n=6) of HepG2 Growth of Cells survival rate
Table 2 compound (I) is on the impact (x ± s, n=6) of L02 Growth of Cells survival rate
Table 3 compound (I) is on the impact (x ± s, n=6) of HepG2 cell ROS level
| Group | Dosage (μm ol/L) | ROS(Fluounit/mgprot) |
| Control group | 0 | 4189±204 |
| Low dosage | 20 | 3215±151 a |
| Middle dosage | 40 | 3080±196 a |
| High dosage | 80 | 2831±212 ab |
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
。
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry leave of Cornus controversa is pulverized by (a), extract with 75 ~ 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 15% ethanol elution, 8 column volumes, then use 75% ethanol elution, 12 column volumes, collect 75% ethanol eluate, concentrating under reduced pressure obtains 75% ethanol elution thing medicinal extract; C in () step (b), 75% ethanol elution thing medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,30:1,10:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 15:1,10:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, be the methanol aqueous solution isocratic elution of 75% by concentration expressed in percentage by volume, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: in step (a), extracts, united extraction liquid with 80% alcohol heat reflux.
4. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
5. a pharmaceutical composition, is characterized in that: this pharmaceutical composition contains the compound according to claim 1 (I) for the treatment of significant quantity and pharmaceutically acceptable carrier.
6. compound according to claim 1 (I) application in the medicine preparing Hepatoma therapy.
7. the application of pharmaceutical composition according to claim 5 in the medicine preparing Hepatoma therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510640790.4A CN105218617A (en) | 2015-09-30 | 2015-09-30 | A kind of new triterpenoid and preparation method thereof and medicinal use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510640790.4A CN105218617A (en) | 2015-09-30 | 2015-09-30 | A kind of new triterpenoid and preparation method thereof and medicinal use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105218617A true CN105218617A (en) | 2016-01-06 |
Family
ID=54987946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510640790.4A Pending CN105218617A (en) | 2015-09-30 | 2015-09-30 | A kind of new triterpenoid and preparation method thereof and medicinal use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105218617A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105153084A (en) * | 2015-09-13 | 2015-12-16 | 金丽秋 | Novel diterpene compound as well as preparation method and medicinal application thereof |
| CN105294817A (en) * | 2015-11-25 | 2016-02-03 | 吕涛 | Novel triterpenoid, preparation method and medical application thereof |
| CN105294818A (en) * | 2015-12-07 | 2016-02-03 | 西宁意格知识产权咨询服务有限公司 | New triterpenoid as well as preparation method and medical application thereof |
| CN105566251A (en) * | 2016-02-20 | 2016-05-11 | 杭州富阳伟文环保科技有限公司 | Novel leucothoe alkane type diterpene compound and preparation method and medical application thereof |
| CN106008543A (en) * | 2016-05-25 | 2016-10-12 | 杭州更蓝生物科技有限公司 | Novel diterpenoid compound and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028323A (en) * | 2007-02-08 | 2007-09-05 | 中国药品生物制品检定所 | Chinese-medicinal composition for treating cough asthma |
| CN101269097A (en) * | 2008-04-30 | 2008-09-24 | 昆明振华制药厂有限公司 | Alstonia-leaf medicinal materials and medicament testing method for its preparation |
-
2015
- 2015-09-30 CN CN201510640790.4A patent/CN105218617A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028323A (en) * | 2007-02-08 | 2007-09-05 | 中国药品生物制品检定所 | Chinese-medicinal composition for treating cough asthma |
| CN101269097A (en) * | 2008-04-30 | 2008-09-24 | 昆明振华制药厂有限公司 | Alstonia-leaf medicinal materials and medicament testing method for its preparation |
Non-Patent Citations (1)
| Title |
|---|
| SOPHIA A. KOLESNIKOVA ET AL.: ""Isolation, structures, and biological activities of triterpenoids from a Penares sp. Marine sponge"", 《JOURNAL OF NATURAL PRODUCTS》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105153084A (en) * | 2015-09-13 | 2015-12-16 | 金丽秋 | Novel diterpene compound as well as preparation method and medicinal application thereof |
| CN105294817A (en) * | 2015-11-25 | 2016-02-03 | 吕涛 | Novel triterpenoid, preparation method and medical application thereof |
| CN105294818A (en) * | 2015-12-07 | 2016-02-03 | 西宁意格知识产权咨询服务有限公司 | New triterpenoid as well as preparation method and medical application thereof |
| CN105566251A (en) * | 2016-02-20 | 2016-05-11 | 杭州富阳伟文环保科技有限公司 | Novel leucothoe alkane type diterpene compound and preparation method and medical application thereof |
| CN106008543A (en) * | 2016-05-25 | 2016-10-12 | 杭州更蓝生物科技有限公司 | Novel diterpenoid compound and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105218617A (en) | A kind of new triterpenoid and preparation method thereof and medicinal use | |
| CN105153084A (en) | Novel diterpene compound as well as preparation method and medicinal application thereof | |
| CN105330716A (en) | New withanolides compound, and preparation method and medical application thereof | |
| CN105330717A (en) | Novel triterpenoid and preparation method and medical application thereof | |
| CN105153269A (en) | New triterpene compounds, and preparation method and medical application thereof | |
| CN105111269A (en) | Novel limonin compound as well as preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105175481A (en) | Highly-oxidized diterpenoid compound and preparation method and medical application thereof | |
| CN105418562A (en) | Diterpenoid compound used for treating the prostatic cancer and preparation method therefor | |
| CN105175265A (en) | Novel diterpenoid compound for treating liver cancer | |
| CN105418545A (en) | Novel isocoumarin compound and preparation method and medical application thereof | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105237380A (en) | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound | |
| CN105566427A (en) | Lanostane triterpene compound, and preparation method and medicinal use thereof | |
| CN105153263A (en) | New limonin compound as well as preparation method and medical application thereof | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN105198897A (en) | New kaurane diterpenoid compound, preparation method and medical application of compound in treating liver cancer | |
| CN105622629A (en) | Kaurane type diterpenoid compound for treating prostatic cancer | |
| CN106397369A (en) | Novel labdane-type diterpenoid compound, preparation method and application thereof, pharmaceutical composition and application of pharmaceutical composition | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer | |
| CN105348227A (en) | Novel isocoumarins compound as well as preparation method and medical application thereof | |
| CN105524134A (en) | Novel lanostane type triterpene compound, preparation method therefor and medicinal use of novel lanostane type triterpene compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 311816 Zhejiang city of Shaoxing province Zhuji city streets after the Song Tao Zhu Song Village No. 80 Applicant after: Song Xiaomei Address before: 325016 Zhejiang Province, Wenzhou city Ouhai District streets Quxi Daitou Road No. 6 Applicant before: Song Xiaomei |
|
| COR | Change of bibliographic data | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160106 |